Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells b1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced b1 integrin in human NSCLC A549 cells. The b1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, b1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that b1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that b1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that b1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.
Introduction
Lung cancer is the leading cause of cancer death worldwide and comprises diseases of diverse aethiology (Jemal et al., 2006) . Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer and has an epithelial origin (Brambilla et al., 2001) . The epidermal growth factor receptor (EGFR) is overexpressed or constitutively activated in approximately 60% of NSCLC cases correlating with poor prognosis. Deregulation of the EGFR signaling contributes to malignancy conferring to transformed cells proliferative advantage, inhibiting apoptosis and favoring cell motility and invasiveness (Sharma et al., 2007) , thus rendering the EGFR the preferential molecule for NSCLC-targeted therapies. However, the current use of EGFR kinase inhibitors presents limitations mainly because nearly all patients become resistant to further treatment (Nguyen et al., 2009; Yoshida et al., 2010) .
Increasing evidences indicate that the integrin family of cell adhesion receptors have an essential role in tumor progression. It is well documented that integrins contribute to migration and invasion of cancer cells (Guo et al., 2006) ; moreover it is becoming evident that they can promote intracellular signaling typically in the context of activated growth factor receptors, thus regulating cell proliferation and survival and sustaining tumor growth (Walker and Assoian, 2005; Klein et al., 2007; Desgrosellier and Cheresh, 2010) . In the context of the NSCLC, increased expression of alpha 5/b1 integrin has been recently reported to be a poor prognostic factor (Adachi et al., 2000; Okamura et al., 2007) , influencing patient survival (Dingemans et al., 2010) .
Our previous data show that in normal epithelial cells b1 integrin is both sufficient to partially activate the receptor itself, and is required for the full activation of the EGFR in response to EGF leading to transcriptional activity (Moro et al., 1998 (Moro et al., , 2002 Cabodi et al., 2009) . Overall, our results contribute to the body of evidences showing that integrins and RPTKs have no longer to be considered as individual receptors, but rather as joint modules in which attachment to the matrix confers positional control to respond to soluble growth factors (Guo and Giancotti, 2004; Streuli and Akhtar, 2009; Cabodi et al., 2010; Desgrosellier and Cheresh, 2010) . Therefore modulating b1 integrin activation or expression might represent a way to interfere with EGFRdependent signaling in cancer cells, in particular in those tumors in which the efficacy of conventional therapeutic regimens aimed to block the EGFR activation is limited. To this regard, b1 integrin may represent a suitable target in lung cancer cells. In this study, we show that b1 integrin has a prominent role in the maintenance of tumorigenic properties of A549 NSCLC cells by regulating EGFR signaling.
Results
b1 integrin-silenced A549 lung cancer cells show a defective response to EGF A549 cell line represents a model for NSCLC expressing high levels of the wt EGFR. To assess their dependence on EGFR, cells were treated with 5 mM of the EGFR kinase inhibitor tyrphostin AG1478, and cell proliferation was assessed by counting cells at different time points. A549 proliferation was inhibited upon the treatment with the inhibitor (Supplementary Figure  S1) , confirming that the cells are addicted to EGFR in their ability to grow in standard culture conditions. We and others have already shown that integrins are able to support EGFR activation either in the absence or in the presence of EGF in normal epithelial cells (Miyamoto et al., 1996; Moro et al., 1998; Bill et al., 2004; Cabodi et al., 2009) . To evaluate whether b1 integrin controls EGFR activation in tumor cells, A549 cells were plated on TS2/16 antibodies against the b1 integrin subunit or kept in suspension in presence and absence of EGF. Consistent with the previous results, EGFR is phosphorylated by b1 integrin-dependent adhesion even in absence of EGF. In addition, in adherent conditions, the treatment with EGF had a synergistic effect on EGFR phosphorylation (Figure 1a) . A similar pattern of activation is observed also for the Erk1/2 MAPKs and Akt (Figure 1a ), demonstrating that in A549 lung cancer cells b1 integrin-mediated adhesion has an essential role in regulating EGFR activation and its downstream signaling.
To assess whether EGFR activity might be modulated by b1 integrin silencing, A549 cells were infected with pLKO.1 lentiviral particles carrying either a b1 integrinspecific short-hairpin RNA sequence or an empty vector. b1 integrin expression was decreased up to 70% compared with control cells, as measured both by western blotting of total cell extracts (Figure 1b, upper panel) and FACS analysis on intact cells. The b3 and b4 integrin expression was also evaluated, showing that their expression on the cell surface remains unchanged in silenced cells (Figure 1b, lower panel) .
In normal growth conditions, silenced cells showed a delayed cell spreading accordingly with the requirement of integrin-activated signaling molecules in the spreading process. The defect was recovered within 12 h of cell adhesion (Supplementary Figure S2) , thus rendering silenced cells undistinguishable from the control ones in normal culture conditions.
To specifically assess the relevance of b1 integrin in A549 response to soluble EGF, control and silenced cells were treated with 20 ng/ml of EGF for different times. Cell extracts were analyzed for EGFR phosphorylation and for the activation of downstream molecules, such as Fak, Src, Erk1/2 MAPKs and Akt. As shown in Figure 1c , silenced cells showed decreased levels of EGFR activation on the signaling-related residues Tyr1068 and Tyr1173, compared with control cells all over the time course of stimulation. Consistently, downstream to EGFR decreased levels of Fak and Src phosphorylation as well as Akt and Erk1/2 were detected. Densitometric analysis (Figure 1d ) indicated that b1 integrin silencing does not impair the kinetics of EGFdependent signaling, but rather affects the extent of the activation at each time point. A similar inhibition of the EGF signaling was also observed in the SK-MES1 lung squamous carcinoma cells silenced for b1 integrin (Supplementary Figure 3a) , further supporting that b1 integrin controls EGFR activity in lung carcinoma cells, and that its silencing is an effective mechanism for modulating receptor activity.
b1 integrin silencing impairs lung tumor cell proliferation and enhances sensitivity to therapy As shown above, A549 cell growth is dependent on EGFR activity. To evaluate the contribution of b1 integrin silencing on their long-term proliferation, A549 cells were plated at low density in normal culture conditions and counted daily until day 12. As shown in Figure 2a , control A549 cells reached the confluence earlier than silenced cells, which displayed a marked decrease in the proliferation rate. Moreover b1 integrin silencing affected cell proliferation at a similar extent also in SK-MES1 cells (Supplementary Figure 3b) . Interestingly, when A549-silenced cells were grown in soft agar, after 2 weeks of culture they gave rise to a number of colonies comparable to that observed in control cells. However, the mean area of colonies was significantly reduced in size and silenced cells never formed colonies larger than 1 mm (Figure 2b ). These data indicate that b1 integrin silencing affects tumor cell proliferation both in anchorage-dependent and independent conditions, underlying the crucial role of b1-dependent signaling in lung tumor cell growth.
Control and silenced A549 cells were then tested for their sensitivity to therapeutic agents. Cells were left untreated or treated for 72 h with different doses of either cisplatin, a DNA-damaging compound, or Gefitinib, a selective EGFR inhibitor (Arteaga and Johnson, 2001) , which are currently in clinical use for NSCLC therapy. The graphs in Figure 2c show that, compared with control cells, silenced cells were more sensitive to cisplatin and Gefitinib, thus indicating that b1 integrin downregulation significantly enhances the ability of lung tumor cells to respond to lower doses of pharmacological agents.
b1 integrin is required for A549 migration and invasive behavior To assess the relevance of b1 integrin in lung tumor cell migration, control and silenced A549 cells were subjected to transwell migration assay. A549 cells do not require additional stimuli to migrate through the Transwell. However, while control cells efficiently migrate in b1 integrin controls EGFR signaling V Morello et al basal conditions, silenced cells showed a 70% reduction in the number of migrating cells (Figure 3a) . Further, control and silenced cells were plated as single cells in a three-dimensional (3D) basement membrane (matrigel/collagen I 1:1) and allowed to grow for 2 weeks. This assay enables to test the ability of cells to invade in a 3D environment, forming typical sprouted structures. When embedded into the matrix, control A549 cells gave rise to sprouted spheroids that extend massive invasive protrusions ( Figure 3b , upper panels). In contrast, b1 integrin-silenced cells formed regular spheroids, without invasive features ( Figure 3b , middle panels). Similar results were also obtained while treating wild-type A549 cells with the anti-b1 inhibitory antibody AIIB2 (29). As EGF is a known inducer of tumor cell invasion (Xue et al., 2006) , to evaluate the 4 A549 b1 ctrl and b1 sh cells were seeded on the upper side of the filters and incubated in 0.1% bovine serum albumin RPMI and let migrate for 6 h. To test the ability of cells to migrate in basal conditions, no additional stimuli were added in the lower chamber. Cells migrating to the lower side were fixed, stained with Diff-Quick kit and counted under a phase-contrast microscope. Numbers on the y-axis represent the number of cells migrated on the lower side of the Transwell. (b, c) Invasion assay. In all, 10 3 A549 wild-type, b1 ctrl and b1 sh cells were embedded as single cells in matrigel/collagen I 1:1 and let grow for 12 days. When indicated, EGF was added for the last 4 days. A total of 10 mg/ ml AIIB2 was added to culture medium on alternate days. Live images were collected by using Zeiss microscopy at Â 4 or Â 20 magnitude. Cell extracts prepared from unstimulated or EGFtreated cells were analyzed for Fak and Src activation, as they are known integrin-dependent regulators of cell migration and invasion (Mitra and Schlaepfer, 2006) . Western blot analysis of Fak and Src phosphorylation, respectively, on Tyr 397 and Tyr 416 revealed that b1 integrin downregulation strongly affects both Fak and Src activation (data not shown). Taken together, these data show that b1 integrin silencing impairs the migratory and invasive behavior of lung tumor cells, affecting the activation of the motility-promoting signaling involving Fak and Src kinases.
b1 integrin affects in vivo tumorigenic properties of A549 cells Crosstalk between integrin receptors and activated growth factor receptors has been demonstrated to have a critical role in the initiation and progression of cancer (Trusolino et al., 2001; Guo et al., 2006; Streuli and Akhtar., 2009; Desgrosellier and Cheresh., 2010; Huck et al., 2010) . Therefore, we decided to investigate in vivo the role of b1 integrin silencing in the process of A549 tumor growth. To this end, we performed xenograft experiments injecting s.c. in SCID mice 3 Â 10 6 control or silenced cells. Even though both cell types gave rise to palpable tumors, the ones derived from silenced cells were significantly smaller compared with those derived from control cells up to the end of the experiment (Figure 4a ). In another experimental set, mice bearing tumors derived from wild-type A549 cells were treated i.p. with two different b1 integrin-blocking antibodies, namely the above mentioned AIIB2 antibody and the BV7 (Cusinato et al., 1999) . As shown in Figure 4a the treatment with b1-blocking antibodies inhibited tumor growth at the same extent of b1 integrin silencing. These results represent the proof of concept of the potential therapeutic benefit of targeting b1 integrin in established lung tumors.
Mice were then sacrificed and tumors derived from control and silenced cells were analyzed for protein expression. As shown in Figure 4b , b1 integrin silencing was highly efficacious and durable also in vivo. The analysis of EGFR, Erk1/2 MAPKs and Akt phosphorylation showed that all these signaling molecules were less phosphorylated in tumors derived from silenced A549 wild-type cells, for a total of six tumors each. Beginning on day 4, mice were injected i.p. bi-weekly either with BV7 10 mg/kg or AIIB2 5 mg/kg in PBS. Tumor volume was measured twice a week within 8 weeks and reported on the y-axis (left panel). At the end of the experiment tumor masses were surgically resected and weighted. The average of tumor weights is reported on the y-axis (*Po0.05). (b) Tumor lysates were analyzed by western blot. The b1 integrin levels as well as EGF-dependent signaling was evaluated in western blot with the indicated phospho-specific antibodies. For normalization purposes membranes were stripped and re-blotted with antibodies for total proteins. Densitometric analysis is reported in arbitrary units as average between different tumors (*Po0.05).
b1 integrin controls EGFR signaling V Morello et al cells. Densitometric analysis (Figure 4b ) of extracts from 13 control and 13 silenced tumors revealed that EGFR and Erk1/2 phosphorylation are significantly reduced in b1 integrin-silenced tumors. Overall these results indicate that b1 integrin sustains in vivo proliferation of A549 cells, likely through an impaired activation of the EGFR signaling cascade.
Dual role for b1 integrin in controlling EGFR turnover and signaling It has been recently demonstrated that integrins can regulate EGFR trafficking from the plasma membrane to the endosomes and back, thus modulating receptor activity (Caswell et al., 2009) .
Thus, to assess whether b1 integrin-dependent control of EGFR turnover could explain the defective EGFR signaling observed in b1-silenced A549 cells, control and silenced cells were analyzed for EGF-dependent EGFR internalization and recycling using 125 I-EGF. As shown in Figure 5a , EGF was internalized with the same kinetics in control and silenced cells both at low (2 ng/ml) (left panel) and high (20 ng/ml) (right panel) EGF doses. Similarly, the rate of EGFR recycling on the cell surface was comparable between the control and silenced cells (Figure 5b ), thus showing that liganddependent EGFR turnover is not affected by b1 integrin silencing.
The experiments described above do not allow analyzing EGFR levels on the plasma membrane in basal conditions in the absence of EGF stimulation. To this end, cells were analyzed by FACS for EGFR levels on the plasma membrane. Interestingly, the amount of EGFR exposed on the cell surface in basal conditions was higher in b1 integrin-silenced cells, compared with the control cells (Figure 5c ). However, consistent with the data obtained with 125 I-EGF, FACS analysis confirmed that, in response to EGF, the rate of EGFR displacement from the plasma membrane was similar in control and silenced cells. Nevertheless, silenced cells showed for each time point an absolute higher value than control cells due to the different basal amount. To confirm this observation, EGFR expression at the cell surface was analyzed by byotinilation of the plasma Immunoprecipitates were blotted with horseradish peroxidase-streptavidin and reprobed with anti-EGFR antibodies. (e) A549 b1 ctrl, b1 sh and b1 sh cells expressing exogenous RCP were starved for 24 h and treated with EGF (20 ng/ml) for the indicated time points. Erk1/2 activation was evaluated with phospho-specific antibodies. Filter was stripped and re-blotted for total Erk1/2. RCP blotting to assess transfected protein levels. Densitometric analysis reports the mean values from two independent experiments. b1 integrin controls EGFR signaling V Morello et al membrane. As shown in Figure 5d , streptavidin western blot of immunoprecipitated EGFR, showed that b1 integrin-silenced cells express an increased amount of cell surface EGFR. Recent evidences point out that EGFR requires alpha 5/b1 integrin and the Rab-associated protein known as RCP for efficient basal endocytic recycling and signaling to Erk (Caswell et al., 2008) . To assess whether the defective signaling observed in b1-silenced cells could be ascribed to an altered function of the b1/RCP pathway, b1-silenced cells were transfected with a plasmid expressing RCP. Indeed, upon RCP overexpression the level of Erk1/2 MAPK activation in response to EGF was partially rescued in silenced cells (Figure 5e ). Thus, these data show that in basal conditions b1 integrin regulates EGFR turnover at the plasma membrane, while EGFR internalization and recycling in response to EGF are not affected by b1 integrin silencing. However, b1 integrin still controls the full propagation of signaling to Erk in response to EGF through the RCP pathway.
Discussion
In this work, we demonstrate that b1 integrin is required for both in vitro and in vivo tumor growth and for migration and invasion of EGFR-dependent NSCLC cells. In addition, we show that b1 integrin controls EGFR signaling and EGFR turnover at the cell membrane. Overall, we provide evidence that b1 integrin/ EGFR crosstalk is a key element driving NSCLC tumorigenesis, thus rendering b1 integrin a suitable target for adjuvant therapy in combination with anti-EGFR agents currently used in clinic.
EGFR is a well-known inducer of lung tumorigenesis, and its expression and activity correlate with tumor onset and maintenance. Less is known on b1 integrin relevance in lung tumors, although its expression has been shown to be aberrant and correlated with reduced patient survival (Okamura et al., 2007; Dingemans et al., 2010) . The results presented in this study are the first demonstration that b1 and EGFR are functionally cooperating in lung cancer cells, giving rise to a crucial signaling platform required for primary tumor formation as well as for the invasive behavior of tumor cells. The relevance of the b1 integrin/EGFR co-operation in the malignant transformation has been underlined in a normal breast line that becomes tumorigenic by acquisition of de novo integrin-EGFR interactions (Wang et al., 1998) . In these cells, function-blocking antibodies to either b1 integrin or EGFR led to a striking reversal to the normal phenotype (Weaver et al., 1997) . Therefore, b1 integrin/EGFR crosstalk appears to be fundamental for cancers that co-express b1 integrin and the EGFR.
Our data show that in A549 cells EGF treatment strictly requires b1 integrin-dependent adhesion for fully activating the EGFR and its downstream signaling. Noteworthy, integrin-dependent adhesion is sufficient not only for triggering EGFR phosphorylation but also for activating downstream pathways. Conversely, in the absence of cell-matrix adhesion, even though EGF triggers a higher EGFR phosphorylation compared with adhesion per se, the signaling molecules Erk1/2 and Akt are not activated, further supporting the essential role of integrin-mediated adhesion in transducing EGF signaling. These data, consistent with previous observations in normal epithelial cells (Boeri Erba et al., 2005; Cabodi et al., 2009) , demonstrate that in lung tumor cells addicted to EGF, signaling remains strictly dependent on cell-matrix adhesion.
Moreover, our data provide evidence that b1 integrin silencing is effective in impairing EGFR signaling to the same extent of the absence of cell matrix adhesion. In fact, b1 integrin-silenced cells that in standard culture conditions maintain normal adhesive properties, are largely defective in EGFR phosphorylation and in activation of downstream signaling molecules. Remarkably, even though the kinetics of activation is not affected, the extent of phosphorylation at each time point is strongly reduced, implying that reduction in b1 integrin results in the inability of EGFR to fully respond to its ligand. Therefore, these data underline the essential role of b1 integrin in determining the cell-matrix dependence of EGFR activity in transformed cells.
Our results clearly show that b1 integrin silencing affects both in vitro and in vivo proliferation of A549 cells, resulting in decreased tumor growth. A similar inhibition on in vivo growth of A549 cells was also observed by treating mice bearing tumor masses with anti-b1 inhibitory antibodies, further assessing the proof of concept of the potential therapeutic benefit of targeting b1 integrin in established lung tumors. Hystochemical analysis of tumors derived from silenced cells revealed that the morphology is not significantly different from the controls, and that the number of vessels is quite similar. Therefore b1 integrin silencing does not affect the general architecture of these tumors neither their ability to recruit new blood vessels, but rather significantly slows down their proliferation, giving rise to tumors that are smaller compared with the control. Interestingly, in tumors derived from silenced cells, EGFR phosphorylation and activation of downstream pathways are severely impaired, indicating that the inhibitory effect of b1 downregulation on EGFR signaling is persistent also in vivo. The observed inhibition of EGFR activity likely accounts for the decreased tumor growth. Therefore, this is the first demonstration that in EGFR-dependent tumors, b1 integrin targeting is an efficient tool to negatively regulate EGFR signaling, thus affecting tumor development.
Tumor progression is a multi-step process involving not only cell proliferation but also migration and invasion of cancer cells to give rise to metastatic dissemination. b1 integrin is a well established player in cell motility (Friedl et al., 2004; Cordes and Park, 2007; Caswell et al., 2009; Friedl and Wolf, 2010) . In this study, we show that its silencing, as well its inhibition, affects the invasive properties of A549 cells, both in terms of directional migration through Transwells and b1 integrin controls EGFR signaling V Morello et al in the ability to invade into 3D matrix. In particular, silenced cells embedded into the 3D matrigel/collagen I matrix organize in spheroids smaller than control ones (data not shown), that do not extend protrusions, whereas control cells give rise to sprouted structures. Consistently, also in the squamous carcinoma A431 cells, b1 integrin silencing gave rise to less invasive tumors (Brockbank et al., 2005) . Although we were unable to perform lung colonization assays with the A549 cells, these in vitro data already clearly support the primary role of b1 integrin in regulating lung cancer cell motility.
Recent work has underlined the relevance of b1 integrins in the control of EGFR endosomal trafficking (Caswell et al., 2009) . It is commonly believed that EGFR internalization through canonical pathways is essential for EGFR signaling (Sigismund et al., 2008; Sorkin and von Zastrow, 2009) . Our data suggest that b1 integrin has a dual role in EGFR internalization and signaling. Indeed, b1 integrin-silenced cells show an increased basal level of EGFR on the cell membrane and a decreased EGFR signaling. Therefore in the absence of b1 integrin, the EGFR on the cell surface is less able to respond to EGF stimulus, not in terms of internalization, but only in terms of signaling. In silenced cells signaling capacity is partially rescued by overexpression of RCP (Caswell et al., 2008) , indicating that RCP/b1 integrin endocytic route is sufficient to sustain EGFR signaling.
In conclusion, our data indicate that silencing b1 integrin on lung cancer cells or treating tumor with antib1 inhibitory antibodies leads to decreased cell proliferation and tumor growth. This effect is particularly important when cells are treated with therapeutic agents. Indeed, silenced cells are sensitive to lower dose of either cisplatin or gefitinib compared with control cells. In clinic, the conventional treatment of NSCLC lung cancer involves the use of surgery, radiotherapy, platinum-base chemotherapy or specific EGFR inhibitors. Although major advances have been made in this field, treatment outcomes for patients affected by advanced NSCLC are still non-efficacious and need to be improved by experimenting novel therapies (Maione et al., 2010) . Therefore, targeting b1 integrin by selective downregulation in combination with conventional therapy might represent a novel adjuvant approach in the context of NSCLC treatment.
Materials and methods

Reagents and antibodies
The monoclonal antibodies TS2/16 to the b1 integrin subunit and HB-8508 to the EGFR were purchased from ATCC (Teddington, UK). Polyclonal Abs anti-EGFR and anti-b1 integrin were described previously (Moro et al., 2002) . Antibodies to Erk1 and to c-Src were from Santa Cruz Biotechnology (Palo Alto, CA, USA). The monoclonal antibodies to Fak were from Millipore (Billerica, MA, USA). Phospho-specific polyclonal antibodies to pEGFR (Tyr 1173), pEGFR (Tyr 1168), pFAK (Tyr 397), pSrc (Tyr 416), p-p42/p44 MAPK (Thr 202/Tyr 204) and pAkt (Ser 473) were purchased from Cell Signalling (Danvers, MA, USA). Human recombinant EGF, cisplatin and secondary antibodies conjugated with peroxidase were from Sigma (St Louis, MO, USA). Secondary antibodies conjugated with FITC were from Alexa Molecular Probes (Invitrogen, Carlsbad, CA, USA). Gefitinib was from SeqChem (Pangbourne, UK). Matrigel and collagen I were from BD Trasduction Laboratories (Franklin Lakes, NY, USA). AG1478 was from Calbiochem (San Diego, CA, USA). AIIB2, a b1 integrin function-blocking antibody was isolated and prepared from a hybridoma cell line (Developmental Studies Hybridoma Bank, Iowa, IA, USA)(29). The BV7 antibody was prepared from a hybridoma cell line already present in the lab.
Cell culture and transfection Culture media, serum and Lipofectamine LTX were from Invitrogen. Human lung adenocarcinoma cell line A549 was purchased from ATCC and grown in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, penicillin/ streptomycin (100 U/ml and 100 mg/ml, respectively) at 37 1C in a 5% CO 2 atmosphere. A549 cells grown to 80% confluence were transiently transfected with the plasmid pEGFP-C3 encoding for RCPwt (kindly provided by Dr. Jim Norman, Beatson Institute for Cancer Research, Glasgow, UK) by the Lipofectamine LTX reagent, as described by the manufacturer. After 24 h, transfection cells were serum deprived and incubated for 24 h before treatment.
Knockdown of b1 integrin by RNA interference b1 integrin short-hairpin RNA sequence in pLKO.1 lentiviral vector (5 0 -AAACCCAGGGCTGCCTTGGAAAAG-3 0 ) (Thermo Scientific, Erembodegem, Germany) or an empty pLKO.1 vector were separately transduced into HEK293T cells along with lentiviral packaging vectors pCMV-dR8.74 and pMD2.G-VSV-G using Effectene reagent (Qiagen, Valencia, CA, USA). Viral supernatants were collected 48 and 72 h after transfection, pooled and filtered. A549 cells grown at 40% confluence in six-well plates were infected either with short-hairpin RNA or with the empty vector in the presence of 8 mg/ml polybrene (Sigma). Transduced cells were kept under puromycin selection (1 mg/ml).
Adhesion assay
Adhesion assay on TS2/16 anti-b1 integrin antibodies-coated plates was performed as described in (Cabodi et al., 2009) .
Protein extraction, immunoprecipitation and western blotting Cell lysis, immunoprecipitation and western blotting were performed as described in (Cabodi et al., 2009) . Protein extracts from tumors were obtained by homogenization in 50 mM Tris (pH 7.4), 10% glycerol, 1% NP-40, 150 mM NaCl, 2 mM EDTA, 2 mM dithiothreitol, 0.4 mM Na3VO4, 10 mM NaF, 0.5 mM phenylmethylsulfonyl fluoride and 40 mg/ml protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Cells were extracted with 1% NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8, 5 mM EDTA, 10 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 and 40 mg/ml protease inhibitor cocktail (Sigma-Aldrich). Image J software (NIH, Bethesda, MA, USA) was used for blot quantification.
Cell migration
For migration assays, transwell chambers were used. A total of 5 Â 10 4 cells were seeded on the upper side of the filters and incubated in 0.1% bovine serum albumin RPMI in the presence, were indicated, of 100 ng/ml EGF (Sigma) in the bottom wells of the chambers. Cells migrating to the lower side b1 integrin controls EGFR signaling V Morello et al were fixed, stained with Diff-Quick kit (Medion Diagnostics AG, Duedingen, Switzerland) and counted under a phasecontrast microscope.
3D assay 3D assays were performed in agreement with protocols reported in: http://muthuswamylab.cshl.edu/protocols. Briefly, A549 cells were embedded as single cells in matrigel/collagen I 1:1 and let grow for 12 days. When indicated, EGF was added for the last 4 days. AIIB2 inhibitory antibody was added to culture medium on alternate days. Live images were collected by using Zeiss microscopy (Oberkochen, Germany) at Â 4 or Â 20 magnitude.
Cell proliferation and soft agar assay A total of 5 Â 10 3 cells were seeded on 6-cm tissue culture dishes and let proliferate for 12 days in the presence of medium supplemented with 10% FCS. Every 2 days, cells were detached and manually counted in Burker chambers on triplicate dishes. For the clonogenic assay, 5 Â 10 4 cells were seeded in 0.4% agar on the top of a base layer containing 0.8% agar into six-well plates. After 2 weeks, colonies were counted under a phase-contrast microscope. ImageJ software (NIH) was used to calculate colonies' area. All of the experiments were performed in triplicate.
Cell surface biotynilation Cell surface biotinylation was performed as described (Damiano et al., 2010) . Cell extracts were immunoprecipitated with EGFR HB8508mAb, and biotinylated fraction was detected by incubation with streptavidin horseradish peroxidase.
Flow cytometry
When indicated cells were treated with EGF. After PBS washing cells were put in trypsin for 2 min at RT and detached by pipetting; then medium was added to block trypsin; after PBS washing, cells were fixed in 1 ml of 1% formaldehyde for 20 min. After a blocking step in 1% bovine serum albumin for 30 min, cell surface labeling of integrins b1, b3 or b4 alternatively was performed using polyclonal rabbit antibodies (dilution 1:500). For EGFR labeling the anti-EGFR mouse monoclonal antibody HB8508, which recognizes the extracellular portion of the receptor was used (dilution 1:1000). Alexa 488-conjugated secondary antibodies were used for detection. In all, 10 4 cells were analyzed at each experimental point by flow cytometry.
I-EGF internalization assay
Internalization assay of 125 I-EGF was performed as described (Tosoni et al., 2005) .
I-EGF recycling assay
Recycling assay of 125 I-EGF was performed as described (Sorkin et al., 1991; Kornilova et al., 1996) .
In vivo tumor growth A total of 5-week-old female SCID mice (C.B-17TM/IcrCrlscidBR) were purchased from Charles River Laboratories (Calco, Italy) and treated in accordance with the European Community guidelines. Mice were challenged subcutaneously bilaterally in the flank with 3 Â 10 6 A549 wild-type, control (b1 ctrl) or silenced (b1 sh) cells suspended in 100 ml of RPMI medium. BV7 and AIIB2 antibodies or non-specific IgG were injected at the indicated doses i.p. biweekly beginning on day 4 after cell implantation.
The incidence and growth of tumors were evaluated twice weekly by measuring with calipers up to the eighth week.
